Mechanism of liposome arsenic trioxide regulating tumor microenvironment and sensitizing tumor immune response after radiofrequency ablation - Scorecard - MDSpire

Mechanism of liposome arsenic trioxide regulating tumor microenvironment and sensitizing tumor immune response after radiofrequency ablation

  • By

  • Chao Liang

  • Shuguang Ju

  • Hao Li

  • Daqian Han

  • Jiacheng Wang

  • Yangyang Niu

  • Jianzhuang Ren

  • Xinwei Han

  • Xuhua Duan

  • June 29, 2026

  • 0 min

Share

Clinical Scorecard: Role of Liposome-Encapsulated Arsenic Trioxide in Modulating Tumor Microenvironment and Enhancing Immune Response Post-Radiofrequency Ablation

At a Glance

CategoryDetail
ConditionHepatocellular Carcinoma
Key MechanismsModulation of tumor microenvironment via HIF-1α downregulation and immune response enhancement.
Target PopulationPatients with hepatocellular carcinoma undergoing incomplete radiofrequency ablation.
Care SettingClinical oncology and interventional radiology.

Key Highlights

  • LATO administration reduces HIF-1α expression in residual tumors.
  • Preoperative LATO enhances immune cell infiltration post-iRFA.
  • Combination therapy with anti-PD-L1 antibody further reduces tumor proliferation.
  • LATO improves therapeutic index by enhancing drug deposition at tumor sites.
  • Systemic ATO has limitations due to pharmacokinetics and toxicities.

Guideline-Based Recommendations

Diagnosis

  • Utilize imaging and biopsy for hepatocellular carcinoma diagnosis.

Management

  • Consider radiofrequency ablation for tumors ≤ 3 cm; larger tumors may require combination therapies.

Monitoring & Follow-up

  • Regularly assess tumor response and immune markers post-treatment.

Risks

  • Monitor for QT interval prolongation and potential cardiac events with ATO.

Patient & Prescribing Data

Patients with hepatocellular carcinoma at risk of incomplete ablation.

LATO may enhance the efficacy of RFA and immune checkpoint inhibitors.

Clinical Best Practices

  • Pre-treat with LATO to optimize outcomes post-radiofrequency ablation.
  • Combine LATO with immune checkpoint inhibitors for improved antitumor response.
  • Monitor patients closely for adverse effects related to arsenic trioxide.

Related Resources & Content

Original Source(s)

Mechanism of liposome arsenic trioxide regulating tumor microenvironment and sensitizing tumor immune response after radiofrequency ablation

  • by Chao Liang, Shuguang Ju, Hao Li, Daqian Han, Jiacheng Wang, Yangyang Niu, Jianzhuang Ren, Xinwei Han, Xuhua Duan

  • June 29, 2026

Related Content

Treatment Patterns and Attrition in Metastatic Castration-Resistant Prostate Cancer

Mixed adenoneuroendocrine carcinoma of the gallbladder: a case report and literature review

ESMO Breast Cancer 2026 Highlights: Pumitamig + DB-1305/BNT325

Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD discuss results from the Pumitamig + DB-1305/BNT325 trial, which were presented at the 2026 ESMO Breast Cancer Congress.

  • June 26, 2026

  • 1 min